Circulating cell-free DNA content as blood based biomarker in endometrial cancer

Lucia Cicchillitti, Giacomo Corrado, Martina de Angeli, Emanuela Mancini, Ermelinda Baiocco, Lodovico Patrizi, Ashanti Zampa, Roberta Merola, Aline Martayan, Laura Conti, Giulia Piaggio, Enrico Vizza

Research output: Contribution to journalArticlepeer-review


Background: Altered circulating cell-free DNA (cfDNA) levels are related to cancer development and aggressiveness. Up to now, very few studies have been performed for evaluating cfDNA content in endometrial cancer (EC). Methods: First, we measured cfDNA release in blood serum of EC cancer patients collected before surgery and before the beginning of any treatment by SYBR Gold assay and correlated it with tumor aggressiveness. We also assessed the relative mitochondrial cell-free DNA (cfmtDNA) content by qRT-PCR. Next, we correlated cfDNA levels with BMI, age, hypertension and inflammation markers. Results: CfDNA levels are higher in G2 and G3 compared with G1 EC sera. A significant modulation of cfDNA content was detected in sera from patients with BMI > 30 compared with those with BMI < 30. We observed a further and significant alteration in cfDNA level in hypertensive patients with G2-G3, but not in G1 EC. Analysis of preoperative neutrophil-to-lymphocyte (NLR) and monocyte-to-lymphocyte (MLR) ratios suggests a contribution of the host response in the altered cfDNA levels in EC. Conclusions: Our data indicate that assessment of total and mitochondrial cfDNA levels in blood sera and the relative NLR and MLR in blood obtained from preoperative patients may help clinical management and prognosis in EC.

Original languageEnglish
Pages (from-to)115230-115243
Number of pages14
Issue number70
Publication statusPublished - Jan 1 2017


  • Bio-markers
  • Circulating cell-free DNA
  • Circulating cell-free mitochondrial DNA
  • Endometrial cancer
  • Liquid biopsy

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Circulating cell-free DNA content as blood based biomarker in endometrial cancer'. Together they form a unique fingerprint.

Cite this